Trastuzumab therapies in human epidermal growth factor receptor 2 cancer

Jingyun Wu; Pianhong Xu; Shinong Zeng

doi:10.54097/hset.v8i.1107

Authors

Jingyun Wu
Pianhong Xu
Shinong Zeng

DOI:

https://doi.org/10.54097/hset.v8i.1107

Keywords:

Monoclonal Antibodies, Trastuzumab, HER-2 Cancer, Therapies.

Abstract

Monoclonal antibodies therapy had shown critical importance in terms of personalized, disease-specific medicine. One example of monoclonal antibody is Trastuzumab, targeting on diseases such as breast cancer. Despite side effects like fever, chills, headache, infection, congestive heart failure, Trastuzumab is proved to be highly effective in experimental studies and clinical practice. Research has shown that through binding with human epidermal growth factor receptor 2, Trastuzumab is able to decrease its signaling pathways and therefore, inhibit cell proliferation and initiate apoptosis. The results of completed clinical trials and ongoing experimental studies, mainly focusing on the combination of trastuzumab and other treatments such as chemotherapy, have shown that compared with monotherapy or traditional conventional treatments such as surgery, radiotherapy, chemotherapy, etc., the combination of trastuzumab has a longer survival period and a lower recurrence rate. Some prime examples are discussed in this review to indicate recent trends of research on this topic. In addition, an in-depth analysis of possible directions of development of this technology is introduced.

Downloads

Download data is not yet available.

References

Trastuzumab. Trastuzumab (Herceptin) | Cancer information | Cancer Research UK. (2021, April 16). Retrieved March 9, 2022, from https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/trastuzumab

Iqbal, N., & Iqbal, N. (2014). Human epidermal growth factor receptor 2 (HER2) in cancers: Overexpression and therapeutic implications. Molecular biology international. Retrieved March 9, 2022, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4170925/

Baselga, J., Perez, E. A., Pienkowski, T., & Bell, R. (2006). Adjuvant trastuzumab: A milestone in the treatment of her-2-positive early breast cancer. The Oncologist, 11(S1), 4–12. https://doi.org/10.1634/theoncologist.11-90001-4

Greenblatt, K. (2021, December 4). Trastuzumab. StatPearls [Internet]. Retrieved March 9, 2022, from https://www.ncbi.nlm.nih.gov/books/NBK532246/

Nanda, S. (2022, March 7). Trastuzumab biosimilar equivalent to referent drug in neoadjuvant setting. oncology.medicinematters.com. Retrieved March 17, 2022, from https://oncology.medicinematters.com/breast-cancer/biosimilars/troika-trastuzumab-biosimilar-equivalent-neoadjuvant-setting/20197364

Hudis, C. A. (2007). Trastuzumab — mechanism of action and use in clinical practice. New England Journal of Medicine, 357(1), 39–51.

Malik, B. (2021, July 5). Understanding how monoclonal antibodies work. StatPearls [Internet]. Retrieved March 9, 2022, from https://www.ncbi.nlm.nih.gov/books/NBK572118/.

O'Mahony, D., & Bishop, M. R. (2006). Monoclonal antibody therapy. Frontiers in bioscience : a journal and virtual library, 11, 1620–1635.

Kreutzfeldt, J., Rozeboom, B., Dey, N., & De, P. (2020). The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies. American journal of cancer research, 10(4), 1045–1067.

Slamon DJ, B Leyland-Jones, S Shak, H Fuchs, VPaton, A Bajamonde, T Fleming, W Eiermann, J Wolter, M Pegram, J Baselga, & L Norton: Use of chemotherapy plus a monoclonal antibody again for metastatic breast cancer that over-express HER2. N Engl J Med 344, 783-792 (2001)

Shitara, K., Baba, E., Fujitani, K., Oki, E., Fujii, S., & Yamaguchi, K. (2021). Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 24(4), 780–789.

FDA approves ado-trastuzumab emtansine for early breast cancer. 2019.

Oostra D and Macrae E. Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press) 2014; 6: 103-113.

Mishima, S., & Shitara, K. (2021). Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer. Expert opinion on biological therapy, 21(7), 825–830.

Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor effcacy with differentiation from T-DM1. Clin Cancer Res. 2016;22(20):5097–108.

Bang, Y. J., Giaccone, G., Im, S. A., Oh, D. Y., Bauer, T. M., Nordstrom, J. L., Li, H., Chichili, G. R., Moore, P. A., Hong, S., Stewart, S. J., Baughman, J. E., Lechleider, R. J., & Burris, H. A. (2017). First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. Annals of oncology : official journal of the European Society for Medical Oncology, 28(4), 855–861.

Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419–30.

National Cancer Institute (2022). Clinical Trials Using Trastuzumab. NIH. https://www.cancer.gov

National Cancer Institute (2022). Testing the Ability to Decrease Chemotherapy in Patients with HER2-Positive Breast Cancer Who Have No Remaining Cancer at Surgery after Limited Pre-operative Chemotherapy and HER2-Targeted Therapy. NIH.https://www.cancer.gov

Murthy, R. K. Tucatinib, Trastuzumab, and Capecitabine for her2-Positive Metastatic Breast Cancer. New England Journal of Medicine 2020, 382 (6), 586–586.

Pegram, M.; Liao, J. Trastuzumab Treatment in Multiple Lines: Current Data and Future Directions. Clinical Breast Cancer 2012, 12 (1), 10–18.